Provided herein are bi-specific lipid nanoparticles (B-LNPs), pharmaceutical compositions comprising the same, and methods of using the same to treat cell proliferative diseases or disorders, e.g., glioblastoma multiforme.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided herein are methods for functionalizing nanoparticles with functional proteins, and methods of using the functionalized nanoparticles. Compositions for preparing the functionalized nanoparticles are also described herein.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
3.
METHODS FOR ASSEMBLING PROTEIN-CONJUGATED NANOCARRIER VACCINES
Provided herein are vaccine compositions for preparing nanocarriers comprising NiVF and NiVG virus proteins. Methods for preparing and using the nanocarriers for eliciting neutralizing antibodies or treating a Nipah virus infection are also described herein.
The present disclosure generally relates to technologies for treating cancer, including brain cancers such as a glioblastoma, methods of increasing the concentration of anthracy clines and immune checkpoint modulators in the brain of a subject, and methods of improving use of immune checkpoint modulators in brain cancers. Also disclosed herein are compositions and methods for treating a brain tumor.
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine liés à un système carbocyclique condensé, p.ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
The present disclosure provides fusion proteins comprises fusion proteins comprising the signal sequence of PduB or PduM and a heterologous protein, as well as constructs for expressing the fusion proteins, and methods of their use. The fusion proteins are designed to deliver the heterologous proteins to bacterial microcompartments and modify the 1,2-propanediol metabolic pathway.
Provided herein are systems comprising magnetically-couplable stents and catheters that allow for locating and retrieving the stents from within a subject. In particular, the systems herein comprise a magnetically-couplable stent and catheter, a guide wire capable of being advanced through the lumens of the stent and catheter, and a retrieval element (e.g., balloon) capable of being advanced through the lumens of the stent and catheter and stably gripping the stent. This method aims to maintain wire access across the pathology that the stent is crossing.
7.
COMPOSITIONS AND METHODS FOR ENHANCING ADOPTIVE T CELL THERAPEUTICS
The present disclosure relates generally to compositions and methods for improving T cell therapy. In particular, the disclosure provides polypeptides and recombinant nucleic acid constructs and/or recombinant nucleic acids encoding polypeptides having mutations capable of altering T cell signaling, cytokine production, and/or in vivo persistence in tumors of therapeutic T cells comprising the mutation. The T cell signaling can be by NF AT, NF-KB and/or AP-1 pathways. The disclosure also provides vectors and cells including the polypeptides and/or recombinant nucleic acid constructs and/or recombinant nucleic acids of the disclosure as well as methods of preparing a T cell for use in cell therapy, and methods of identifying a mutation useful for improving T cell therapy.
The present disclosure is generally directed to a method of monitoring and treating a disorder and a system for monitoring and treating a disorder. The method includes monitoring a subject, determining a time period that the risk of an adverse event, such as a risk of stroke provoked by a cardiac arrhythmia (such as atrial fibrillation AFib), is elevated, and administering a medical treatment or notifying a patient to begin a treatment, such as starting to take daily a direct acting oral anticoagulant DOAC. The system includes a device to monitor the patient that is communicatively coupled to a server. The server receives monitoring data from the device and transmits the data to a storage database. In response to the device detecting data indicative of a meeting or exceeding a predetermined threshold, the server sends a notification to the patient via the device.
G16H 20/10 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p.ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p.ex. pour s’assurer de l’administration correcte aux patients
Provided herein are endoscopes with a transparent balloon mounted thereon that find use in angioscopy and cardioscopy. In particular, an endoscope-mounted balloon with a transparent lining that can be inflated with transparent liquid and apposed to the wall of a blood vessel or the heart allows visualization of the adjacent structures through the balloon.
A61B 1/06 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments avec dispositifs d'éclairement
10.
GLYCOCAP: A CELL-FREE GLYCOSYLATION PLATFORM FOR CLICKABLE AZIDO-SIALOGLYCAN PRODUCTION
Disclosed herein are components, kits, platforms, and systems for novel, bacterial-based, cell-free glycosylation for incorporating non-canonical sugars and constructing azido-sialoglycoprotein structures.
Provided herein are biopanning methods for identifying peptides that bind to one or more glial cell subtypes, and peptides identified using the methods described herein. In some embodiments, provided herein are biopanning methods for identifying peptides that bind to glial cell subtypes including surveying glial cells, active glial cells, and/or primed glial cells.
Convolution-Hierarchical Deep-learning Neural Network (C-HiDeNN) is a customized neural network that can solve and train partial differential equations for various Computational Science and Engineering (CS&E) problems including but not limited to linear/nonlinear solid mechanics problems, damage/fracture problems, thermal and fluid problems, multiphysics and multiscale problems, and many more. Compared to classical numerical methods such as Finite Element Analysis (FEA), C-HiDeNN is much more accurate and faster due to the architecture of hierarchical deep neural networks (DNNs) with convolution layers. The training of C-HiDeNN renders versatile local and global mesh adaptivity which further improves the efficiency of the numerical method.
A system to perform reversible transvenous electroporation includes an electroporation generator and a controller operably coupled to the electroporation generator. The controller is configured to instruct the electroporation generator to generate a voltage signal to perform electroporation, where the voltage signal has a predetermined range of voltages and a predetermined range of pulse widths to ensure that the electroporation is reversible, and where the voltage signal is biphasic or monophasic. The controller also delivers the voltage signal to a catheter to perform the electroporation, where the catheter includes one or more electrodes through which the voltage signal is delivered.
A61N 1/02 - SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE ÉLECTROTHÉRAPIE; MAGNÉTOTHÉRAPIE; THÉRAPIE PAR RADIATIONS; THÉRAPIE PAR ULTRASONS Électrothérapie; Circuits à cet effet - Parties constitutives
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
14.
CONVOLUTION HIDENN-TENSOR DECOMPOSITION FOR MANUFACTURING SIMULATION, PERFORMANCE PREDICTION, AND TOPOLOGY OPTIMIZATION OF MULTISCALE MATERIAL SYSTEMS
Convolution-Hierarchical Deep-learning Neural Network – Tensor decomposition (C-HiDeNN-TD) has four features: (1) Tensor decomposition breaking down the whole design into small tractable problems; (2) Convolution built-in filter to increase accuracy without adding extra DoFs; (3) Convolution built-in filter can avoid checkerboard pattern; (4) Design can have arbitrary smoothness without adding extra DoFs.
Disclosed is minimal essential media for culturing induced human pluripotent stem cells (iPSCs), methods for preparing the media, and methods of using the media.
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
A61K 47/56 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
C07H 19/00 - Composés contenant un hétérocycle partageant un hétéro-atome du cycle avec un radical saccharide; Nucléosides; Mononucléotides; Leurs anhydro-dérivés
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p.ex. contenant des motifs CpG
An acupressure device includes a mount that is configured to attach to a patient and one or more indenter devices attached to the mount. An indenter device is mounted such that the indenter device is positioned over an acupuncture location of the patient. The indenter device has a base that contacts the mount and a tip that contacts the acupuncture location on the patient.
A61H 39/04 - Dispositifs pour exercer des pressions auxdits endroits, p.ex. shiatsu
A61N 1/18 - Application de courants électriques par électrodes de contact
A61F 13/06 - Bandages ou pansements; Garnitures absorbantes spécialement conçus pour les pieds ou les jambes; Coussinets pour cors; Anneaux pour cors
A61H 11/00 - Ceintures, bandes ou peignes pour massage
A61H 23/00 - Massage par percussion ou vibration, p.ex. en utilisant une vibration ultrasonique; Massage par succion-vibration; Massage avec des membranes mobiles
18.
AUTOMATED DETECTION AND TRACKING OF CORTICAL BLOOD VESSEL TEMPERATURE DURING NEUROSURGERY
Cortical blood vessel temperature is automatically detected and tracked during an interventional procedure, such as during a neurosurgical procedure. In general, the temperature of blood vessels on the surface of the brain are identified and tracked using data from a brain thermography device, which may include an infrared ("IR") thermal camera. Thermal data are segmented and vessel segments are identified and tracked based on the segmentation. The corresponding temperature measurements for each vessel segment are tracked over the frames of thermal data to track the temperature of blood vessels over time.
An antifouling tile includes a tile blank having a first surface and a second surface opposite the first surface. The antifouling tile also includes a plurality of photocatalytic particles mounted to the first surface of the tile blank. The antifouling tile further includes an ultraviolet (UV) light source mounted to the second surface of the tile blank. The UV light source activates the plurality of photocatalytic particles to prevent biofouling of the tile blank.
B63B 59/04 - Moyens pour éviter la salissure de la coque
B01J 19/12 - Procédés utilisant l'application directe de l'énergie ondulatoire ou électrique, ou un rayonnement particulaire; Appareils à cet usage utilisant des radiations électromagnétiques
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
Disclosed herein are methods and composition for reprocessing crosslinked polyurethanes. The method may comprise mechanically processing the crosslinked polyurethane, mixing the mechanically processed crosslinked polyurethane with a solid polyurethane exchange catalyst, heating the mixture to an effective bond-exchange temperature, and applying mechanical force to the mixture for an effective bond-exchange time. In another aspect the method may comprise heating a polyurethane exchange catalyst and an antioxidant composition, the antioxidant composition comprising the crosslinked polyurethane and an antioxidant, to an effective bond- exchange temperature and applying mechanical force to the polyurethane exchange catalyst and the antioxidant composition for an effective bond-exchange time.
C08J 11/10 - Récupération ou traitement des résidus des polymères par coupure des chaînes moléculaires des polymères ou rupture des liaisons de réticulation par voie chimique, p.ex. dévulcanisation
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
C08G 18/22 - Catalyseurs contenant des composés métalliques
B01J 31/18 - Catalyseurs contenant des hydrures, des complexes de coordination ou des composés organiques contenant des complexes de coordination contenant de l'azote, du phosphore, de l'arsenic ou de l'antimoine
ANN & ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Shah, Nikhil Dipak
Reddy, Narainsai K.
Yamada, Akira
Alias, Basil
Abrégé
A handle assembly for a gouge includes a handle, where a distal end of the handle includes first threads. The handle assembly includes a grip that has an interior channel. At least a portion of the interior channel includes second threads that mate with the first threads on the distal end of the handle to secure the grip to the handle. The handle assembly also includes a collet. A distal end of the collet includes an opening that is sized to receive a proximal end of a gouge. The handle assembly further includes a collar that is sized to receive the collet, and that mounts onto a distal end of the grip.
The present invention provides bispecific antibodies that target T cells to melanoma cells. The bispecific antibodies comprise a first single-chain variable fragment (scFv) that binds to the T cell co-receptor CD3ε and a second scFv that binds to the melanoma marker protein tyrosinase- related protein 1 (TYRP1). Methods of using the bispecific antibodies to treat tumors and lyse target cells are also provided.
A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
C07K 16/30 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
23.
CATALYTIC CHEMICAL RECYCLING OF POLYAMIDE-BASED PLASTICS
Provided are circuits for integrating image processing into image sensors. Multiple configurations of sensors are described which generate specific motion and shape-based responses to changes in received light intensity. These sensor configurations may be used to pre-process images and to provide additional context to light intensity data. The sensor configurations may include memory circuits and signal conditioning.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
NORTHWESTERN UNIVERSITY (USA)
Inventeur(s)
Frankowski, Kevin
Wang, Feijun
Huang, Sui
Freeman, Emma
Abrégé
The current invention relates to transcription elongation factor eEFlA2-targeted protein degradation ligands and pharmaceutical compositions thereof and their utility as anti-cancer agents.
Disclosed are substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs). The substituted heterocycles disclosed herein are shown to be useful in inhibiting c-MYC. The disclosed PROTACs are shown to induce degradation of c-MYC protein. The substituted heterocyclic compounds and proteolysis-targeting chimeric molecules (PROTACs) disclosed, herein may be utilized as therapeutics for treating cancer and cell proliferative disorders.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
A61K 31/166 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome de carbone d'un groupe carboxamide lié directement au cycle aromatique, p.ex. procaïnamide, procarbazine, métoclopramide, labétalol
A61K 31/167 - Amides, p.ex. acides hydroxamiques ayant des cycles aromatiques, p.ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p.ex. lidocaïne, paracétamol
The present disclosure relates generally to an enzyme building block for the assembly of megamolecules. The system is based on the inhibition of the human-derived cellular retinoic acid binding protein II (CRABP2) domain. The inventors synthesized a synthetic retinoid bearing an arylfluorosulfate group, which uses sulfur fluoride exchange click chemistry to covalently inhibit CRABP2. The inventors conjugated both the inhibitor and a fluorescein tag to an oligo( ethylene glycol) backbone and measured a second-order rate constant for the protein inhibition reaction of approximately 3,600 M-1s-1. The inventors used this new enzyme-inhibitor pair to assemble multi-protein structures in one-pot reactions using three orthogonal assembly chemistries to demonstrate exact control over the placement of protein domains within a single, homogeneous molecule. This work enables a new dimension of control over specificity, orientation, and stoichiometry of protein domains within atomically precise nanostructures.
Provided herein are balloon delivery systems (BDSs) for deploying expandable implants at treatment locations within a subject. In particular provided herein are BDSs providing optimal deployment of bioresorbable vascular scaffolds (BVS), for example, within a coronary artery.
A61F 2/958 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes ballons gonflables pour insérer les stents ou les endoprothèses déployables couvertes
A61F 2/01 - Filtres implantables dans les vaisseaux sanguins
A61F 2/966 - Instruments spécialement adaptés pour insérer ou retirer les stents ou les endoprothèses déployables couvertes possédant une gaine extérieure avec un mouvement longitudinal relatif entre la gaine extérieure et la prothèse, p.ex. utilisant une tige poussoir
A61F 2/86 - Stents ayant une forme caractérisée par des éléments filiformes; Stents ayant une forme caractérisée par une structure de type filet ou de type à mailles
31.
POLAR ETHYLENE-BASED POLYMER WITH REVERSIBLE CROSSLINKER
The present disclosure provides a crosslinkable polymer composition. In an embodiment, the crosslinkable polymer composition includes a polar ethylene-based polymer, a free radical initiator, and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate). The present disclosure provides a crosslinked composition. In an embodiment, the crosslinked composition includes a polar ethylene-based polymer; and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate).
Disclosed are protein-like polymers and uses thereof. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide that (i) inhibits aggregation of, (ii) accelerates aggregation of, (iii) binds to, and/or (iv) mimics: (a) at least a portion of Tau protein, and/or (b) at least a portion of microtubulin protein.
Disclosed herein are single crystal imine-linked 2D-covalent organic frameworks (COFs), methods of making and using the same. In some embodiments, the imine-linked 2D-covalent organic frameworks are used to separate a mixture.
B01J 20/22 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation contenant une substance organique
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
B01J 20/281 - Absorbants ou adsorbants spécialement adaptés pour la chromatographie préparative, analytique ou de recherche
The present disclosure relates generally to hypoxia biosensors. In particular, the present disclosure relates to hypoxia biosensors that employ engineered genetic circuits for enhanced biosensor sensitivity and response. Some engineered genetic circuits employ positive feedback and amplification of expression in order to promote high-efficiency reporting of hypoxia.
The present disclosure provides a crosslinkable polymer composition. In an embodiment, the crosslinkable polymer composition includes an ethylene-based polymer, a free radical initiator, and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate). The present disclosure provides a crosslinked composition. In an embodiment, the crosslinked composition includes an ethylene-based polymer; and 2,2,6,6-tetramethyl-4-piperidyl methacrylate disulfide (BiTEMPS methacrylate).
Provided herein are devices for prolonged securement of medical devices to a subject. In particular, drain tubes (e.g., percutaneous drains), catheters, and other medical devices are secured near the insertion site using the devices herein.
Provided herein are devices for sutureless securement of medical devices to a subject. In particular, drain tubes (e.g., percutaneous drains), catheters, and other medical devices are secured to the skin of a patient (e.g., near the insertion site) using the devices herein.
THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (USA)
NORTHWESTERN UNIVERISTY (USA)
Inventeur(s)
Burke, Martin, D.
Jewett, Michael, Christopher
Bogart, Jonathan, Webb
Ghaffari, Saba
Abrégé
Disclosed are polypeptides and methods of glycosylating the C19 hydroxyl group of AmdeB (i.e., amphotericin B lacking the sugar moiety) comprising contacting AmdeB with a saccharide in the presence of one of the polypeptides. The methods access compounds that are analogues of amphotericin B with a modified sugar moiety that have an improved therapeutic index, such as C2'epiAmB. Also disclosed are pharmaceutical compositions comprising the compounds and a pharmaceutically acceptable carrier.
C07H 17/08 - Hétérocycles d'au moins huit chaînons, p.ex. érythromycines
C12P 19/62 - Préparation d'O-glucosides, p.ex. glucosides avec un atome d'oxygène du radical saccharide lié directement à un hétérocycle autre que saccharide ou à un système cyclique condensé contenant un hétérocycle autre que saccharide, p.ex. coumermycine, novobiocine l'hétérocycle comportant au moins huit chaînons et uniquement l'oxygène comme hétéro-atome du cycle, p.ex. érythromycine, spiramycine, nystatine
39.
MATERIALS AND METHODS FOR MODIFYING EXPRESSION OF MYOSIN HEAVY CHAIN GENES
Described herein is a method for increasing expression of the MHY6 gene in a cell by genome editing comprising introducing into the cell one or more DNA endonucleases within or near enhancer regions of the MYH6 gene that results in activation of enhancer regions of the MYH6 gene.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Sharma, Arun
Bury, Matthew
Sharma, Tiffany
Gunasekaran, Muthukumar
Kaushal, Sunjay
Abrégé
Disclosed herein are composition and methods for treating a subject having intestinal inflammation. The methods comprise administering an effective amount of c-Kit+ CD45-mesenchymal stem cells to a subject in need of a treatment for intestinal inflammation.
Hierarchical metallic supra-nanostructure (HMSN) comprising branches with alternating nanocrystals and nano-linkers, where the nanocrystals comprise gold and the nano-linkers comprise a second metal having a lower reduction potential than the nanocrystals, are disclosed. The nano-linkers may selectively dissolve in the presence of reactive oxygen species (ROS). Also disclosed are methods of. making and using the same.
A method of forming a hydrophobic conductive substrate includes forming a metal thin film on a substrate and coating with a hydrophobic coating. For example, the hydrophobic coating can be a self-assembled monolayer of phosphonic acid.
C23C 22/03 - Traitement chimique de surface de matériaux métalliques par réaction de la surface avec un milieu réactif laissant des produits de réaction du matériau de la surface dans le revêtement, p.ex. revêtement par conversion, passivation des métaux au moyen de solutions non aqueuses contenant des composés du phosphore
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c. à d. procédés de dépôt chimique en phase vapeur (CVD) caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
B05D 3/10 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliqués; Traitement ultérieur des revêtements appliqués, p.ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par d'autres moyens chimiques
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
43.
METHODS AND SYSTEMS FOR IDENTIFYING NOVEL ALLOSTERIC TRANSCRIPTION FACTOR OPERATORS, AND NOVEL NUCLEIC ACIDS
Disclosed herein are methods and systems to generate novel nucleic acid sequences that bind to an allosteric transcription factor and novel nucleic acid sequences generated by said methods.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p.ex. liaison anticorps-antigène, liaison récepteur-ligand
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
44.
SYSTEMS AND METHODS FOR CELL-FREE ITERATIVE SITE SATURATION MUTAGENESIS AND ITS APPLICATION FOR THE DIRECTED EVOLUTION OF ENZYMES CATALYZING UNNATURAL REACTIONS
Disclosed are methods, compositions, systems, and protein compounds for the directed evolution of enzymes and proteins. The method comprising generating variant protein with a desired functionality, comprising one or more DNA expression templates comprising nucleic acid sequences encoding a variant protein, expressing the variant protein using cell-free protein synthesis; and analyzing one or more parameters associated with the variant protein.
Disclosed are methods, devices, kits, components, and compositions for detecting a target molecule in a test sample using a cell-free protein synthesis (CEPS) reaction. The methods, devices, kits, components, and compositions may be utilized for detecting target molecules, such as lead, from environmental or biological samples.
C12N 15/115 - Aptamères, c. à d. acides nucléiques liant spécifiquement une molécule cible avec une haute affinité sans s'y hybrider
C12Q 1/6825 - Détecteurs faisant intervenir la détection d’acides nucléiques
C12Q 1/6897 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques faisant intervenir des gènes rapporteurs liés de façon fonctionnelle à des promoteurs
The invention discloses a megasonically exfoliated two-dimensional (2D) nanomaterial ink. The megasonically exfoliated 2D nanomaterial ink is then aerosol-jet printed (AJP) onto printed graphene electrodes to achieve all-AJP, flexible photodetectors. The 2D nanomaterial AJP ink is designed with terpineol, a high boiling point solvent, which enables a highly ordered thin-film morphology and also improves the photogenerated charge transport. After printing, the photodetectors are photonically annealed, which provides quasi-ohmic contacts and photoactive channels with responsivities that outperform previously reported all-printed visible photodetectors by over 3 orders of magnitude. Megasonic exfoliation coupled with AJP allows the superlative optoelectronic properties of ultrathin nanosheets to be utilized in the scalable additive manufacturing of mechanically flexible optoelectronics.
A method for non-invasive assessment of vascular 4D hemodynamics includes receiving standard anatomic imaging data at a local network or cloud-based analysis platform and identifying a vessel of interest from the received anatomic imaging data. The method also includes deriving hemodynamic features from the vessel of interest from the received anatomic imaging data using deep learning by inputting the received anatomic imaging data into a deep learning network. The method further includes calculating 4D hemodynamic parameters and generating output data based on the hemodynamic features derived from the vessel of interest.
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p.ex. pour analyser les cas antérieurs d’autres patients
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
48.
METHODS AND SYSTEMS FOR INDIVIDUAL ION MASS SPECTROMETRY
Disclosed herein are methods and systems for individual ion mass spectrometry (I2MS). The methods and systems described herein parse I2MS data and allows for informed tandem mass spectrometry analyses by determining a target m/z that increases the yield of an intact mass corresponding to an analyte of interest while reducing the yield of additional detectable masses.
A system for harvesting fog that includes a core, where the core features a rod-like structure that is configured to direct accumulated fog droplets in a downward direction. The system also includes a plurality of trichomes mounted to the core such that each of the trichomes is configured to accumulate the fog droplets. Interstitial spaces are formed in between trichomes to wick the fog droplets and coalesce them into one or more continuous fluid streams along a length of the core. The system collects the accumulated fog droplets and directs them in a downward direction along the core towards a bulk outflow.
The invention relates to an electrotherapy system comprising a pair of electrodes coupled with a region of interest of a subject for providing electrostimulation thereto; and a wireless platform coupled with the pair of electrodes for operable providing power to the stimulator.
Described herein are engineered polynucleotides comprising chimeric antigen receptors (CAR) comprising a single chain antibody to IL13Rα2 (scFv); and IL15. The encoded proteins are expressed as IL13Rα2 scFv/IL15 fusion proteins, as well as soluble IL15. Also, described herein are CAR T cells expressing the encoded proteins, and methods of their use.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present disclosure describes immune-ethanol ablation compositions comprising ethanol and curcumin for treatment of solid tumors. Also described herein are methods of using the immune-ethanol ablation compositions to treat solid tumor cancers and enhance anticancer immune activation.
A method of forming a bioactive pattern on a substrate can include contacting a substrate comprising a prepolymer ink coated thereon with a beam pen lithography pen array. The prepolymer ink can include a photoinitiator, an acrylate, and a thiol-modified or acrylate-modified functional binding molecule. The method can further include irradiating the beam pen lithography pen array to transmit the radiation through the pens and out the exposed tip to controllably irradiate the prepolymer ink to initiate selectively photopolymerization of the prepolymer ink and form a pattern of thiol-functionalized cross-linked polymer printed indicia on the substrate; and exposing the pattern of the thiol-functionalized cross-linked polymer printed indicia in a biomolecule containing solution under conditions sufficient to bind the biomolecule to the thiol- functionalized cross-linked polymer printed indicia to form the bioactive pattern.
B01J 19/00 - Procédés chimiques, physiques ou physico-chimiques en général; Appareils appropriés
B05D 5/00 - Procédés pour appliquer des liquides ou d'autres matériaux fluides aux surfaces pour obtenir des effets, finis ou des structures de surface particuliers
G03B 27/52 - Appareils de tirage par projection, p.ex. agrandisseur, appareil photographique de reproduction - Détails
Provided herein are compositions comprising dual-porosity membranes an microporous outer layer and a nanoporous inner layer, and methods of use thereof. In particular, polycarbonate-based polyurethane bilayer membranes are formed in the presence of pore-forming agents that allow for differ pore sizes to be achieved in inner and outer layers. The dual-porosity membranes herein find use in encapsulating therapeutic cells for transplantation.
B32B 5/32 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par la présence de plusieurs couches qui comportent des fibres, filaments, grains ou poudre, ou qui sont sous forme de mousse ou essentiellement poreuses les deux couches étant sous forme de mousse ou essentiellement poreuses
B32B 5/18 - Produits stratifiés caractérisés par l'hétérogénéité ou la structure physique d'une des couches caractérisés par le fait qu'une des couches contient un matériau sous forme de mousse ou essentiellement poreux
B32B 27/40 - Produits stratifiés composés essentiellement de résine synthétique comprenant des polyuréthanes
55.
ORGANIC ELECTROCHEMICAL TRANSISTOR AS AN ON-SITE SIGNAL AMPLIFIER FOR ELECTROCHEMICAL APTAMER-BASED SENSORS
Analyte sensing devices that include an electrochemical aptamer-based (E-AB) sensor integrated with an organic electrochemical transistor (OECT) for signal amplification are provided. The E-AB sensor has a three-electrode setup that includes an aptamer-functionalized working electrode, an independent reference electrode, and a counter electrode composed of a mixed ionic-electronic conductive polymer. In the sensors, the working electrode simultaneously serves as a gate electrode for an OECT, while the mixed ionic-electronic conductive polymer also acts as the transistor channel of the OECT. This integrated device design retains the features of both the E-AB sensor and the OECT, thereby enabling electrochemical measurements to be carried out by the E-AB sensor, while simultaneously monitoring changes in the in-plane conductivity of the OECT channel.
The present disclosure provides methods and compositions for targeting lipid bilayer particles, such as secreted extracellular vesicles, and cargo entities included therein to recipient cells.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
57.
CROSS-LINKED TUMOR LYSATE SPHERICAL NUCLEIC ACIDS AS CANCER VACCINES
The disclosure is generally related to cross-linked tumor lysate spherical nucleic acids (CLSNAs), nanostructures comprising a core to which a shell of oligonucleotides is attached. Methods of making and using the CLSNAs are also provided herein. In some aspects, the disclosure provides a cross-linked tumor lysate spherical nucleic acid (CLSNA) comprising: (a) a core comprising a plurality of cross-linked tumor cell antigens; and (b) a shell of oligonucleotides attached to the external surface of the core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides.
The present disclosure relates generally to methods and compositions for loading cargo entities into lipid bilayer particles, such as cell-derived membrane particles, e.g., secreted extracellular vesicles.
The disclosure is generally related to calcium salted spherical nucleic acids (SNAs). SNAs comprise a nanoparticle core surrounded by a shell of oligonucleotides. In some aspects, the disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; and (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, wherein one or more oligonucleotides in the shell of oligonucleotides comprises a phosphate backbone; the SNA comprising Ca2+ ions adsorbed to the phosphate backbone of one or more oligonucleotides in the shell of oligonucleotides. Methods of making and using the SNAs are also provided herein.
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c. à d. autres que des liaisons 3'-5' phosphodiester
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
C12N 15/117 - Acides nucléiques présentant des propriétés immunomodulatrices, p.ex. contenant des motifs CpG
61.
METHODS OF TREATING IMMUNOTHERAPY-ASSOCIATED ADVERSE EFFECTS
Described herein are methods of treating an immunotherapy-associated adverse event in a subject in need thereof comprising detecting a level of NKG2D receptor ligand polypeptide (and optionally IL-18) in a sample form the subject; and (b) administering either (1) a corticosteroid or (2) a TNFα inhibitor or an integrin inhibitor to the subject.
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/566 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet utilisant un support spécifique ou des protéines réceptrices comme réactifs pour la formation de liaisons par ligand
An oxygenation system producing oxygen for therapeutic cells housed in an implanted or external device, the oxygenation system comprising a first electrode comprising a first material layer stack and a catalyst film of a high surface area or catalyst particles on which at least one catalyst for electrocatalytic oxygen evolution reaction is disposed; and a second electrode comprising a second material stack.
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
C25B 11/073 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par le matériau Électrodes comportant des électro-catalyseurs sur un substrat ou un support caractérisées par le matériau électro-catalytique
C25B 9/73 - Assemblages comprenant plusieurs cellules du type filtre-presse
C25B 15/08 - Alimentation ou vidange des réactifs ou des électrolytes; Régénération des électrolytes
C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
Disclosed herein are methods for preparing a copolymer from homopolymers. The method comprises compounding a bond-exchange catalyst and a polymer composition comprising a first homopolymer and a second homopolymer at an effective bond-exchange temperature for an effective bond-exchange time in a compounder, thereby preparing a compounded melt. Also disclosed is a method for preparing a compatibilized blend comprising compounding the copolymer prepared by a method described herein and a second polymer composition at a compatibilization temperature for a compatibilization time in a compounder.
In an aspect, the invention provides therapeutic agents comprising brush polymers that address challenges associated with conventional administration of free therapeutic peptides. In an embodiment, for example, the invention provides brush polymers incorporating one or more therapeutic peptides comprising a sequence having 75% or greater sequence identity with an 8 to 12 amino acid fragment of SEQ ID NO: 218 (MDLIDILWRQDIDLGVSREVFDFS). Therapeutic agents of the invention comprising brush polymers include high-density brush polymers including cross-linked brush polymers, brush block copolymers, and brush random copolymers. In an embodiment, brush polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of making and using therapeutic agents comprising brush polymers.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 47/62 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant une protéine, un peptide ou un acide polyaminé
66.
MASS SPECTROMETRY METHODS FOR DETERMINING GLYCOPROTEOFORM-BASED BIOMARKERS
Disclosed herein are mass spectrometry methods for determining glycoproteoform-based biomarkers. The methods comprise identifying, with a processor from mass spectrometry data of the glycoprotein, a set of glycoproteoforms where each of the glycoproteoforms have a measurable intact mass; generating, with the processor from the identified set of glycoproteoforms, a glycoproteoform network separated by saccharide features, determining, with the processor from the glycoproteoform network, a site-independent prediction of N-glycans mapped to biosynthesis pathways; and generating, with the processor from the determined N-glycans mapped to biosynthesis pathways, a glycan structure. The methods may be used to analyze a glycoprotein in a subject, analyze disease progression, or identify disease onset or recovery.
Provided herein are self-assembling peptides comprising hyaluronic acid binding domains, nanofibers and systems comprising the same, and methods of use thereof.
An ionogel includes an ionic liquid electrolyte (ILE) comprising an ionic liquid (e.g., 1-ethyl-3-methyl-imidazolium bis(fluorosulfonyl)imide (EMIM-FSI)) and a lithium salt (e.g., lithium bis(fluorosulfonyl)imide (LiFSI)) dissolved in the ionic liquid; and a solid matrix material comprising hexagonal boron nitride (hBN) nanoplatelets mixed with the ionic liquid electrolyte in at least one solvent.
Disclosed are protein-like polymers and uses thereof. In an aspect, the invention provides brush protein-like polymers that address challenges associated with conventional administration of free therapeutic peptides. The protein-like polymers generally comprise a polymer of formula (FX1). The polymer of formula (FX1) in some aspects comprises a peptide having similarity or homology to a Myc binding peptide sequence. The brush protein-like polymers of the invention include high-density brush polymers including brush block polymers and brush statistical polymers. In an embodiment, brush protein-like polymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration.
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C08L 85/00 - Compositions contenant des composés macromoléculaires obtenus par des réactions créant dans la chaîne principale de la macromolécule une liaison contenant des atomes autres que le silicium, le soufre, l'azote, l'oxygène et le carbone; Compositions contenant des dérivés de tels polymères
C08G 81/00 - Composés macromoléculaires obtenus par l'interréaction de polymères en l'absence de monomères, p.ex. polymères séquencés
A transient closed-loop system for cardiac pacing and/or defibrillator therapy for a subject includes a bioresorbable module configured to at least partially attach to an epicardial interface of the subject's heart for the cardiac pacing; at least one skin-interfaced module configured to attach to an outer surface of the subject's skin, wherein the bioresorbable module is in wireless communication with the at least one skin-interfaced module; and a control module in wireless communication with the at least one skin-interfaced module.
Composites of metal-organic framework particles and bacterial cellulose, methods of making the composites, and methods of using the composites in the hydrolysis of organic compounds are provided. The composites, which are aerogels comprising metal-organic framework particles embedded in a bacterial cellulose nanofiber network, are fabricated using a microbial synthesis strategy in which bacterial cellulose nanofiber is biosynthesized using a cellulose-producing bacteria in a fermentation medium in which metal-organic framework particles are dispersed.
Disclosed herein are systems for electron catalyzed molecular recognition and methods of making and using the same. The system comprises an electron source for providing an electron, a redox-active substrate capable of accepting the electron from the electron source, and a catalytic intermediate formed noncovalently from the substrate and a second molecule, wherein the energy barrier for forming the catalytic intermediate is decreased by the redox-active substrate accepting the electron from the electron source.
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 4/86 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes inertes ayant une activité catalytique, p.ex. pour piles à combustible
B01J 23/38 - Catalyseurs contenant des métaux, oxydes ou hydroxydes métalliques non prévus dans le groupe des métaux nobles
B01J 35/02 - Catalyseurs caractérisés par leur forme ou leurs propriétés physiques, en général solides
73.
UNIVERSAL METHOD FOR SYNTHESIS OF METALLIC NANOPARTICLES VIA SCANNING PROBE LITHOGRAPHY
A method for forming metal or metal oxide nanoparticles on a substrate can include depositing a precursor ink on a hydrophobic surface of a substrate to form nanoreactors on the hydrophobic surface. The precursor ink includes a metal precursor and a non- coordinating polymer dissolved in a solvent. The process can then include evaporating the solvent from the nanoreactors, wherein upon evaporation of the solvent, the polymer and the metal precursor phase separate and the metal precursor aggregates on a surface of the nanoreactors. After the solvent is evaporated, the polymer is removed to thereby leave the aggregated metal precursor in contact with the hydrophobic surface. The resulting aggregated metal precursor is then annealed to form the metal or metal oxide nanoparticle.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p.ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). In particular, disclosed are toxic RNAi sequences in polyplexes or lipopolyplexes comprising a dsRNA having a first strand, otherwise referred to as an "A" strand, and a second strand, otherwise referred to as a "B" strand, wherein the region A02-A07 of the dsRNA is GGGGGC, and methods of using said the same for killing cancer cells and treating cancer.
A method of simultaneously testing catalytic activity and/or selectivity of a plurality of catalyst includes coating a substrate having the plurality of catalyst with a polymer thin film having one or more reactive probes, subjecting the coated substrate to catalysis conditions corresponding to the target catalytic activity and/or selectivity, and imaging the coated substrate for the optical signal. Each reactive probe has a signaling component that generates an optical signal upon reaction of the probes with a product of the target catalytic activity and/or selectivity, thereby allowing sensing and signaling of the product of the target catalytic activity and/or selectivity. The presence of an optical signal in one or more regions of the coated substrate is indicative of catalysts of the plurality of catalyst in the one or more regions being active for the target catalytic activity and/or selectivity.
A method of forming a combinatorial mixed halide perovskite library can include depositing an array of halide perovskite particles on a substrate. The method further includes exposing the array of halide perovskites to a laser to from defects in each of or a selected portion of the halide perovskite particles. The exposure conditions are modified across the array to generate a variation of defect concentration in the halide perovskite particles in the array. The defect containing halide perovskites are then exposed to an ion exchange solution and either anion exchanged or cation exchanged to thereby form a mixed halide perovskite particle.
C30B 7/02 - Croissance des monocristaux à partir de solutions en utilisant des solvants liquides à la température ordinaire, p.ex. à partir de solutions aqueuses par évaporation du solvant
B82Y 30/00 - Nanotechnologie pour matériaux ou science des surfaces, p.ex. nanocomposites
B82Y 40/00 - Fabrication ou traitement des nanostructures
Polyurethane waste blending using dynamic urethane exchange and twin-screw extrusion is described. The method may comprise introducing the polyurethane composition into a compounding device, heating the polyurethane composition to an effective bond-exchange temperature, and compounding the polyurethane composition for an effective bond-exchange time where the polyurethane composition comprises two or more network polymers and an effective amount of a polyurethane exchange catalyst permeated within the polyurethan composition.
C08G 18/10 - Procédés mettant en œuvre un prépolymère impliquant la réaction d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs, dans une première étape réactionnelle
C08G 18/70 - Polymérisats d'isocyanates ou d'isothiocyanates avec des composés contenant des hydrogènes actifs caractérisés par les isocyanates ou isothiocyanates utilisés
C08G 18/72 - Polyisocyanates ou polyisothiocyanates
79.
REPROCESSABLE ADDITION-TYPE POLYMER NETWORKS BASED ON DYNAMIC HINDERED UREA BONDS
Methods and compositions for making organic crosslinkers having hindered urea bonds and methods and compositions for making dynamic crosslinked polymer networks using the organic crosslinkers via addition chemistry are provided. Also provided are methods for processing and reprocessing the dynamic crosslinked polymer networks in which the crosslinkers dissociate at elevated temperatures and recombine upon cooling. Polymer networks formed using the dynamic crosslinkers can be reprocessed multiple times at modest temperatures with full recovery of crosslink density.
C08J 3/24 - Réticulation, p.ex. vulcanisation, de macromolécules
C08G 59/18 - Macromolécules obtenues par polymérisation à partir de composés contenant plusieurs groupes époxyde par molécule en utilisant des agents de durcissement ou des catalyseurs qui réagissent avec les groupes époxyde
C08J 3/00 - Procédés pour le traitement de substances macromoléculaires ou la formation de mélanges
80.
SMALL MOLECULE DIRECTED URINARY BLADDER TISSUE REGENERATION
ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Sharma, Arun
Fuller, Natalie, J.
Bury, Matthew
Abrégé
Disclosed are methods for regenerating bladder tissue. More specifically, disclosed are methods of regenerating bladder tissue by administering aryl hydrocarbon receptor effectors to a subject in need thereof.
Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). In particular, disclosed are toxic RNAi sequences comprising a dsRNA having a first strand, otherwise referred to as an "A" strand, and a second strand, otherwise referred to as a "B" strand and dinucleotide repeats. Also included are methods of using said complexes for killing cancer cells and treating cancer.
The present disclosure generally provides compositions and methods for increasing the activity of an annexin protein to treat a cellular membrane injury in a patient in need thereof. In some aspects, the disclosure provides methods of treating a patient suffering from a nerve injury comprising administering a therapeutically effective amount of a composition comprising an agent that increases the activity of an annexin protein. In further aspects, the disclosure provides methods of reducing serum or plasma level of lactate dehydrogenase (LDH), cardiac troponin T, cardiac troponin I, creatine kinase (CK), or a combination thereof, in a patient in need thereof, comprising administering a therapeutically effective amount of an agent that increases the activity of an annexin protein to the patient.
A61K 38/02 - Peptides à nombre indéterminé d'amino-acides; Leurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal
A61P 21/00 - Médicaments pour le traitement des troubles du système musculaire ou neuromusculaire
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
83.
SYSTEMS AND METHODS FOR EFFICIENT ELECTRICAL GENERATION FROM LIQUID FUELS
The present disclosure provides methods for generating electricity. In embodiments, a method for generating electricity comprises injecting a liquid fuel composition comprising a hydrocarbon and water into a reformer, the reformer under a pressure and at an elevated temperature to convert the liquid fuel composition to a reformate composition via a reforming reaction, the reformate composition comprising hydrogen and methane; and introducing the reformate composition into an anode inlet port of a solid oxide fuel cell in fluid communication with the reformer while introducing oxygen into a cathode inlet port of the solid oxide fuel cell under conditions to convert the reformate composition into an exhaust composition while generating electricity. Systems for carrying out the methods are also provided.
H01M 8/0612 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux à partir de matériaux contenant du carbone
H01M 8/0606 - Combinaison d’éléments à combustible avec des moyens de production de réactifs ou pour le traitement de résidus avec des moyens de production des réactifs gazeux
H01M 8/22 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible dans lesquels le combustible est à base de matériaux comprenant uniquement des éléments autres que le carbone, l'oxygène ou l'hydrogène
H01M 8/2425 - Groupement d'éléments à combustible, p.ex. empilement d'éléments à combustible avec électrolytes solides ou supportés par une matrice Éléments à haute température avec électrolytes solides
H01M 8/18 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Éléments à combustible; Leur fabrication Éléments à combustible à régénération, p.ex. batteries à flux REDOX ou éléments à combustible secondaires
84.
AMINE REAGENTS AND PROCESSES FOR ARTIFICIAL MELANIN NANOPARTICLES FOR HAIR DYES
Provided herein are methods, compositions and associated formulations for hair treatment utilizing artificial melanin precursors and one or more amine compounds. In aspects, the one or more amine compounds facilitate alkaline conditions during the hair treatment, while being more tolerable to the hair, subject, and/or administrator compared to other conventional alkaline agents.
Disclosed herein are agents that target telomerase reverse transcriptase (TERT) for treating cancer and sensitizing cancer cells to genotoxic therapy. The methods include inhibiting induction of an immunosuppressive factor in a subject in need thereof, the method comprising administering an inhibitor of TERT to the subject.
C07D 405/02 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles
C07D 405/06 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne carbonée contenant uniquement des atomes de carbone aliphatiques
C07D 309/32 - Composés hétérocycliques contenant des cycles à six chaînons comportant un atome d'oxygène comme unique hétéro-atome du cycle, non condensés avec d'autres cycles comportant deux liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
86.
INCOMPLETE AUTOPHAGY INDUCTION FOR THE TREATMENT OF CANCER
Disclosed herein are methods and compositions for treating cancer using an incomplete autophagy inducer, such as metixene (aka. "methixene"), to trigger caspase-mediated apoptosis in cancer cells. The described methods and compositions can cause a significant decrease in tumor size and a significant prolongation in survival. The methods and compositions are useful for the treatment of cancers, such as brain cancer, breast cancer, lung cancer, and melanoma.
The invention provides an implantable device and method of monitoring wirelessly and continuously thermal conductivity and blood flow on the surface of a target region of a subject. The implantable device comprises a probe operably attached to the target region; and an electronic module coupled with the probe for wireless, real-time, and continuous measurements of physiological information of the target region.
Disclosed are substituted indole compounds and other substituted nitrogen-containing heteroaryl compounds. The disclosed compounds and compositions thereof may be utilized in methods for inhibiting kalirin, including methods for treating and/or preventing diseases or disorders associated with kalirin activity or expression such as neuropathic pain, chronic pain, and epilepsy.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p.ex. carbazole
A61K 31/407 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des systèmes hétérocycliques, p.ex. kétorolac, physostigmine
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines
89.
POLYMER COMPOSITIONS FOR VERTICAL CHANNEL ORGANIC ELECTROCHEMICAL TRANSISTORS
Photocurable compositions that combine redox-active semiconducting organic polymers with photocurable organic molecules are provided. Upon exposure to radiation, the photocurable compositions form ion-permeable, electrically conductive crosslinked organic films that can be used as conducting channels in n-channel or p-channel organic electrochemical transistors, including vertical organic electrochemical transistors (vOECTs). The vOECTs can be incorporated in complementary electronic circuits.
C08F 2/50 - Polymérisation amorcée par énergie ondulatoire ou par rayonnement corpusculaire par la lumière ultraviolette ou visible avec des agents sensibilisants
B32B 27/30 - Produits stratifiés composés essentiellement de résine synthétique comprenant une résine acrylique
C08F 220/18 - Esters des alcools ou des phénols monohydriques des phénols ou des alcools contenant plusieurs atomes de carbone avec l'acide acrylique ou l'acide méthacrylique
C09D 133/08 - Homopolymères ou copolymères d'esters de l'acide acrylique
C09D 133/10 - Homopolymères ou copolymères d'esters de l'acide méthacrylique
C09D 133/12 - Homopolymères ou copolymères du méthacrylate de méthyle
G03F 7/028 - Composés photopolymérisables non macromoléculaires contenant des doubles liaisons carbone-carbone, p.ex. composés éthyléniques avec des substances accroissant la photosensibilité, p.ex. photo-initiateurs
A smart face mask device includes a housing that is designed to mount to a personal protective face mask and a memory within the housing that is configured to store sensor data. The device includes one or more sensors configured to generate the sensor data during use of the personal protective mask. The device also includes a processor operatively coupled to the memory and configured to process the sensor data to determine information regarding a user of the personal protective mask, and to transmit the information regarding the user to a remote application.
The present disclosure is directed to multicomponent assemblies (e.g., crystalline structures) using oligonucleotide dendrimers and spherical nucleic acids (SNAs). The disclosure also provides methods of forming the multicomponent assemblies.
A device for reversibly blocking activities of a target region of a subject includes a microfluidic system configured to route a fluid around the target region to change a local temperature of the target region; and an electronic system coupled with the microfluidic system for providing a real-time feedback.
A61B 18/02 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci par refroidissement, p.ex. techniques cryogéniques
A61B 18/00 - Instruments, dispositifs ou procédés chirurgicaux pour transférer des formes non mécaniques d'énergie vers le corps ou à partir de celui-ci
A61B 17/00 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets
93.
FUNCTIONALIZED CYCLODEXTRIN MONOMER AND POLYMER FOR WATER REMEDIATION
Disclosed herein are mesoporous polymeric materials and methods for preparing and using the same. The mesoporous polymeric material comprises a network of cyclodextrin moieties crosslinked by a plurality of crosslinks.
B01J 20/28 - Compositions absorbantes ou adsorbantes solides ou compositions facilitant la filtration; Absorbants ou adsorbants pour la chromatographie; Procédés pour leur préparation, régénération ou réactivation caractérisées par leur forme ou leurs propriétés physiques
C02F 1/28 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par absorption ou adsorption
94.
COMPOSITIONS FOR INHIBITING DIPEPTIDE REPEAT PROTEIN-RIBOSOMAL RNA INTERACTION AND USES THEREOF
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (USA)
Inventeur(s)
Wolin, Sandra
Boccitto, Marco
Cano, Juan Alberto Ortega
Kiskinis, Evangelos
Abrégé
The present disclosure relates generally to compositions and methods for inhibiting dipeptide repeat protein (DPR)-ribosomal RNA (rRNA) interaction. In particular, the present technology relates to administering a therapeutically effective amount of one or more compositions that inhibit DPR-rRNA interaction to a subject diagnosed with, or at risk for DPR-associated pathologies, e.g., amyotrophic lateral sclerosis or frontotemporal dementia.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
95.
WT-IDH1 INHIBITION USING A COVALENT AND BRAIN-PENETRANT SMALL MOLECULAR INHIBITOR FOR FERROPTOSIS INDUCTION IN HIGH-GRADE GLIOMA
Disclosed are methods of treating diseases or disorders associated with the expression of wild type isocitrate dehydrogenase 1 (IDH1). The disclosed methods may be utilized to treat diseases or disorders associated with cell proliferation, including cancer.
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
C07D 239/70 - Composés hétérocycliques contenant des cycles diazine-1, 3 ou diazine-1, 3 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques
96.
SPHERICAL NUCLEIC ACIDS FOR CGAS-STING AND STAT3 PATHWAY MODULATION FOR THE IMMUNOTHERAPEUTIC TREATMENT OF CANCER
The disclosure is generally directed to spherical nucleic acids (SNAs), nanostructures with a core surrounded by a radial presentation of oligonucleotides, that can activate a cytoplasmic DNA sensor including but not limited to cyclic GMP-AMP synthase (cGAS). In some embodiments, the SNAs also inactivate a transcription factor including but not limited to signal transducer and activator of transcription 3 (STATS). Methods of making and using the SNAs are also provided herein. In some aspects, the present disclosure provides a spherical nucleic acid (SNA) comprising (a) a nanoparticle core; and (b) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising a double-stranded or single-stranded stem loop DNA oligonucleotide that activates cyclic GMP-AMP synthase (cGAS) and is at least 15 base pairs in length.
METHODS FOR PERFORMING HIGH-SPEED, SCANNED LASER STRUCTURING OF MULTI-LAYERED ECO-BIORESORBABLE MATERIALS AND FABRICATING BIORESORBABLE ELECTRONIC DEVICES, AND APPLICATIONS THEREOF
This invention relates to methods for performing laser structuring of multi-layered ecoresorbable or bioresorbable materials and fabricating a bioresorbable electronic device using pisosecond-pulsed laser, devices fabricated by the methods, and applications of the same. Specifically, the method includes: sequentially forming a plurality of ecoresorbable or bioresorbable material layers on a flexible substrate; patterning, locally thinning or ablating, using a picosecond-pulsed laser system, the ecoresorbable or bioresorbable material layers to form sensing components and interconnection traces of the bioresorbable electronic device; and patterning and ablating, using a picosecond-pulsed laser system, the flexible substrate to form stretchable portions of the bioresorbable electronic device. The material layers may be formed on the flexible substrate by physical lamination, transfer printing, deposition or growth techniques. The use of the picosecond-pulsed laser is advantageous because the ablation process occurs on timescales sufficiently short to limit thermal diffusion and the associated spread of the heat-affected zone.
A61B 5/293 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61L 31/14 - Matériaux caractérisés par leur fonction ou leurs propriétés physiques
In an aspect, the invention provides compositions comprising brush block copolymers incorporating a combination of targeting agents and therapeutic agents. Compositions of the invention comprising brush block copolymers include high-density brush polymers for the targeted delivery of therapeutic agents. In an embodiment, brush block copolymers of the invention exhibit proteolysis-resistant characteristics and maintain their biological function during formulation and administration. The invention also includes methods of using compositions comprising brush block copolymers.
C07K 14/00 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p.ex. poudres
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/42 - Protéines; Polypeptides; Leurs produits de dégradation; Leurs dérivés p.ex. albumine, gélatine ou zéine
Disclosed are nanoparticles comprising directionally attached antibodies and compositions for use in locoregional delivery, including intra-tumoral and transarterial chemoembolization (TACE), and methods of making the nanoparticles. Also disclosed are methods for treating a subject in need thereof the compositions described.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
A method of performing automatic ion control for mass spectrometry includes acquiring, by charge detection mass spectrometry, a mass spectrum comprising a plurality of peaks representing intensity as a function of mass-to-charge ratio (m/z) of a population of ions analyzed by a mass analyzer during an acquisition event. Based on the mass spectrum, a measured signal density of a selected m/z range of the mass spectrum is determined. An ion population control parameter for a subsequent acquisition event is set based on the measured signal density and a target signal density. The ion population control parameter regulates a population of ions analyzed by the mass analyzer during the subsequent acquisition event.
brevets
